Wellnex Life (ASX:WNX) — Material Events
ASX:WNX · 15 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Wellnex Life to Sell Pain Away for Up to A$21.3 Million, Targeting Debt-Free StatusMedium
Wellnex Life to sell Pain Away business for up to A$21.3 million, aiming for debt repayment and strategic focus
6 Aug 2026
·Asset Sale Agreement
·85
Wellnex Life Grows Revenue 40% While Narrowing Core Losses in FY25Medium
Wellnex Life FY25 revenue up 40%, normalised EBITDA loss narrows 57%, net assets rise 86%
29 Aug 2025
·Appendix 4E – Preliminary Final Report
·80
Wellnex Life Grows Revenue 40% but Losses Deepen Amid Strategic ExpansionMedium
Wellnex Life FY25 revenue up 40%, loss widens; balance sheet strengthened by AIM listing
29 Aug 2025
·Appendix 4E Preliminary Final Report
·75
Wellnex Life’s Turnaround Gains Momentum with EBITDA Boost and New Distribution DealsMedium
Wellnex Life posts H1 FY26 EBITDA growth and breakeven Q2, expands distribution
16 Jan 2026
·Market Update
·75
Wellnex Life Expands Haleon Partnership with UAE Softgel OrderMedium
Wellnex Life secures UAE order with Haleon, boosting 2025 revenue forecasts
22 Sept 2025
·Company Update
·75
Wellnex Life Edges Toward Profitability with Strong Pain Away GrowthMedium
Wellnex Life reports positive turnaround progress with EBITDA profit and strong Pain Away sales
16 Dec 2025
·Trading Update
·75
Wellnex Life Narrows Focus as Cash Flow Improves Sharply in Q2 FY26Medium
Wellnex Life posts improved cash flow and 31.5% revenue growth in Q2 FY26, focusing on core brand strategy
29 Jan 2026
·Quarterly Update and Appendix 4C
·75
Wellnex Life Posts 40.5% Revenue Growth, Eyes Margin RecoveryMedium
Wellnex Life posts 40.5% revenue growth in FY25, margin recovery underway
30 Sept 2025
·Annual Report
·75
Wellnex Life Secures Key Supply Deal Extension with Haleon UKMedium
Wellnex Life extends licensing and supply agreement with Haleon UK to March 2027
2 Apr 2026
·Contract Extension
·70
Wellnex Life Secures Additional A$2.5M Loan to Fuel Growth AmbitionsMedium
Wellnex Life expands A$2.5M financing facility to support growth
19 Sept 2025
·Capital Raising
·70
Wellnex Life Eyes Strategic Moves to Boost Pain Away and Repay Director LoansMedium
Wellnex Life explores acquisition interest and convertible note funding to drive Pain Away expansion and business turnaround
9 Feb 2026
·Company Update
·70
Wellnex Life CEO Steps Down Amid $2.3M Loan Repayment PlanMedium
Wellnex Life CEO resigns; loan repayment terms agreed
21 Oct 2025
·Directorate Change and Loan Repayment
·70
Wellnex Life Navigates Q1 Sales Dip, Exits Medicinal Cannabis, Secures $5.35M DebtMedium
Wellnex Life Q1 FY26 sales down 18%, exits medicinal cannabis, secures $5.35M debt facility
20 Oct 2025
·Quarterly Cash Flow and Operational Update
·70
Wellnex Life CEO Karafotias Resigns, Bozinovski Takes Sole HelmMedium
Wellnex Life joint CEO George Karafotias resigns; Zack Bozinovski to become sole CEO
15 Aug 2025
·Executive Resignation
·60
Wellnex Life Extends $2.88M Director Loan Repayment and Rehires Former CEO as ConsultantMedium
Wellnex Life extends $2.88M loan repayment deadline and appoints former CEO as consultant
23 Apr 2026
·Loan Repayment Extension and Executive Appointment
·50
No articles in this tier for the last 12 months.
Market Mentions
5
- appeared in market wrap coverage
These are market wrap articles where Wellnex Life (ASX:WNX) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 32 (3 Aug -> 7 Aug) 2026
8 Aug 2026
Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026
8 Aug 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026
14 Feb 2026